{"url":"https://api.github.com/repos/allenai/scispacy/issues/236","repository_url":"https://api.github.com/repos/allenai/scispacy","labels_url":"https://api.github.com/repos/allenai/scispacy/issues/236/labels{/name}","comments_url":"https://api.github.com/repos/allenai/scispacy/issues/236/comments","events_url":"https://api.github.com/repos/allenai/scispacy/issues/236/events","html_url":"https://github.com/allenai/scispacy/issues/236","id":629114159,"node_id":"MDU6SXNzdWU2MjkxMTQxNTk=","number":236,"title":"Wrong named entities report (unbalanced brackets)","user":{"login":"iacopy","id":4771794,"node_id":"MDQ6VXNlcjQ3NzE3OTQ=","avatar_url":"https://avatars.githubusercontent.com/u/4771794?v=4","gravatar_id":"","url":"https://api.github.com/users/iacopy","html_url":"https://github.com/iacopy","followers_url":"https://api.github.com/users/iacopy/followers","following_url":"https://api.github.com/users/iacopy/following{/other_user}","gists_url":"https://api.github.com/users/iacopy/gists{/gist_id}","starred_url":"https://api.github.com/users/iacopy/starred{/owner}{/repo}","subscriptions_url":"https://api.github.com/users/iacopy/subscriptions","organizations_url":"https://api.github.com/users/iacopy/orgs","repos_url":"https://api.github.com/users/iacopy/repos","events_url":"https://api.github.com/users/iacopy/events{/privacy}","received_events_url":"https://api.github.com/users/iacopy/received_events","type":"User","site_admin":false},"labels":[{"id":4505790237,"node_id":"LA_kwDOCPNzOc8AAAABDJDnHQ","url":"https://api.github.com/repos/allenai/scispacy/labels/model%20improvement","name":"model improvement","color":"f9d0c4","default":false,"description":""}],"state":"open","locked":false,"assignee":null,"assignees":[],"milestone":null,"comments":2,"created_at":"2020-06-02T11:08:51Z","updated_at":"2022-09-07T02:55:49Z","closed_at":null,"author_association":"NONE","active_lock_reason":null,"body":"Hi, I just report problematic named entities I found using `en_core_sci_sm`, to improve the model. Most of them contain unbalanced brackets.\r\n\r\n```\r\n(-2)-0-(+2\r\n(-8\r\n(= control values\r\n(= controls\r\n(= group b\r\n(= proliferating \r\n(= week-4\r\n(0.3\r\n(1)h nmr) spectroscopy\r\n(125)i-aβ(1\r\n(13)c)-labeled\r\n(1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol\r\n(3.6\r\n(7.3\r\n(7.6\r\n(7.9\r\n(9\r\n(arg1,phe5)-ha(aha\r\n(auc)(0\r\n(bmi)>25 kg/m(2\r\n(e)-2-[(e)-but-2-en-1-yl-idene]hydrazinecarboxamide}\r\n(me-17030)-(not significant\r\n(p=1x10\r\n(plga)/(met-loaded\r\n(s/t)px(k/h/r\r\n(taaaa)(n\r\n[(18)f]-2-fluoro-2-deoxy-d-glucose ([(18)f]fdg\r\n[(3)h]o-methyl-d-glucose (\r\n[1\r\n[1,2\r\n[1.9\r\n[2\r\n[3\r\n[3h]mpp(+\r\n[5\r\n[6-(3)h]glucose and [u-(14)c]alanine\r\n[6,6\r\n[6.3\r\n[d-leu-4]-ob3\r\n[methoxy-(11)c]pd-153035\r\n[nle27]ghrh-(1\r\n[prl1\r\n*\r\n* metformin\r\n**\r\n**p\r\n*10\r\n*2\r\n*3\r\n*3d\r\n∆(4\r\n∆i(30)/∆g(30\r\n+\r\n+/-\r\n+/-standard deviation\r\n++\r\n1,25-dihydroxyvitamin d(3\r\n1.05).conclusions\r\n1.432[1.068\r\n1.91[- \r\n100)%\r\n13c]lactate:[1\r\n15-epi-lipoxin a(4\r\n1h nmr) spectroscopy\r\n2-(n\r\n2-amino-4-(dimethyl-amino)-7-methyl-5,7-dihydro-6h-[1,3,5]triazepin+ ++-6-one\r\n2-deoxy-[1,2-(3)h]-glucose\r\n2,3,4,5-tetrachlorophenol (\r\n2.55[1.64;3.96\r\n2009).a\r\n29)-nh2\r\n2a) resolution\r\n3-(4-methanesulfonylphenoxy)-n-[1-(2-methoxy-ethoxymethyl)-1h-pyrazol-3-yl]-5-(3-methyl pyridin-2-yl)-benzamide\r\n3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide\r\n3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide\r\n3-dioleoyloxy-propyl)-trimethylammonium/cholesterol/dspe-peg-anisamide aminoethyl\r\n3.7(0.8\r\n3(2\r\n311+g(d\r\n33.5(6.6\r\n36)amide\r\n3tw(pm\r\n4-[(2e)-n'-(2,2'-bithienyl-5-methylene)hydra-zinecarbonyl]-6,7-dihydro-1-phenyl-1h-pyrazolo[3,4-d]pyridazin-7-one\r\n4(1/2\r\n43.20(30.1\r\n5-dimethylthiazol-2-yl)-2\r\n5/33(15\r\n50.(abstract truncated\r\n50.(abstract truncated\r\n57.4]).the hazard ratio\r\n5ht(2c\r\n6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine\r\n6-[ethyl-(3-isopropoxy-4-isopropylphenyl)amino\r\n7-[(3r)-3-(1-aminocyclopropyl)pyrrolidin-1-yl]-1-[(1r,2s)-2-fluorocyclopropyl]-8-methoxy-4-oxoquinoline-3-carboxylic acid\r\n7.65)%\r\n9)nonapeptide-ethylamide\r\na(-/-\r\na(+/-\r\na(1c\r\na1c)\r\nabdominal) fat mass\r\nability.(abstract truncated\r\nability.(abstract truncated\r\nabsorption enhancer sodium n-(8-[2-hydroxybenzoyl\r\nac2+)\r\nacarbose treatment.(abstract truncated\r\nacc2 ki)\r\nacid bis-[6-methyl-heptyl\r\nacrylic acid)-grafted-gellan\r\nactive.(abstract truncated\r\nacute pancreatitis(ap\r\nadenosine monophosphate-activated protein kinase)-dependent manner\r\nadipoq)\r\nadjusted odd ratio(aor\r\nadma-metabolizing enzyme) activity\r\nadults.(abstract truncated\r\naflatoxin b(1\r\naflatoxin b(1\r\nage-adjusted r(s\r\nagent(s\r\nagents(metformin\r\nageoptical density(oad\r\nagonist)-stimulated activity\r\nagonist/5-ht(2a\r\naha(s\r\nakt ser(473\r\nalbufera natural park (spain\r\nalcl(3\r\naldh(+\r\nalone.(abstract truncated\r\nalone.(abstract truncated\r\nalzheimer'sdisease(ad\r\nam)/liver kinase b1\r\nam1241 (2-iodo-5-nitrophenyl)-[1-(methylpiperidin-2-ylmethyl)-1 h-indol-3-yl]methanone\r\namerican psychological association)\r\namino)-2-deoxyglucose\r\namp-activated protein kinase) pathway\r\namp-activated protein kinase) signalling\r\nampk-α(1\r\nampk(thr172\r\nampkα(1/2\r\nampkα(s173\r\nampyra®)\r\nand(c\r\nand(or\r\nandhemoglobin a1c(a1c\r\nang ii)-induced hypertension\r\nang ii)-treated renal fibroblast nrk-49f\r\nang-(1\r\nangiotensin ii)-infusion\r\nanti)advanced\r\nantidiabetic agent(s\r\nantineoplastic agent(s\r\nantineoplastic agent(s\r\nantipsychotic(s\r\napical mpp(+\r\napoa1(-/-\r\napoe(-/-\r\napoe(-/-)/ampkalpha2(-/-\r\napoe(-/-)/ampkα1(-/-\r\napolipoprotein (\r\napoptosis-related ets-like 1 transcription factor(elk-1\r\napparent v(max\r\nare(s\r\narg-phe-nh2 (\r\narg(972\r\narizona sexuel experience) scale\r\naromatic) bonds\r\narteriograph®)\r\nascending p-ampkα(-thr172\r\nasp(+\r\nassociated (\r\nassociation(s\r\nasymmetric ν(v-o\r\natcc crl-1550) cancer\r\natm-ampk-p53/p21(cip1\r\nauc(∞\r\nauc(0\r\nauc(0-)(infinity\r\nauc(0-6h\r\nauc(0-last\r\nauc(0-proportional to\r\nauc(0-t\r\nauc(0,24 h\r\nauc(0,infinity\r\nauc(0:30\r\nauc(45\r\nauc(60\r\nauc(a\r\nauc(e2\r\nauc(gluc\r\nauc(glucagon\r\nauc(inf\r\nauc(ins\r\nauc(insulin\r\nauc(lqc\r\nauc(tau\r\nauc[0:29\r\nauc[24\r\naudio-video sexual stimulation(χ²=34.422\r\naurc(lh\r\nautoimmune) diabetes mellitus\r\navandamet® (\r\naverage hemoglobin a(1c\r\nb(0.22±0.13\r\nb(1\r\nb(12\r\nb) pathway\r\nb6-lep(ob/ob\r\nb6.v-lep(ob/ob\r\nbafilomycin a(1\r\nbasal hemoglobin a(1c\r\nbased)-classical methods\r\nbaseline-adjusted hba(1c\r\nbaseline(53.6\r\nbasis).participant\r\nbcl(xl\r\nbel/fu) cells\r\nbeta-(4-dimethylamino phenyl\r\nbeta-(4-dimethylamino phenyl\r\nbeta1(186\r\nbhr),group ii\r\nbiasp 30)\r\nbilateral internal capsules.(abstract truncated\r\nbilateral internal capsules.(abstract truncated\r\nbind as(iii\r\nbiphasic insulin aspart 70/30 (biasp70/30\r\nbiphenyl]-3-yl)methoxy)phenoxy)acetic acid\r\nbis-2-(ethylhexyl\r\nbis(n'n'-dimethylbiguanidato)oxovanadium(iv\r\nbl21(de3\r\nblue)-binding method\r\nbmi 26.3+/-3.3 kg/m(2\r\nbmi<25kg/m(2\r\nbmi>32 kg/m(2\r\nbmi≥25kg/m(2\r\nbody mass index 28.5+/-0.6 kg/m(2\r\nbody mass index>30kg/m(2\r\nbody-mass index ≤45 kg/m(2\r\nbody-mass index 45 kg/m(2\r\nbowel.(abstract truncated\r\nbowel.(abstract truncated\r\nbrain cells(2\r\nbreast reconstruction(ibr\r\nbritish national formulary (joint formulary committee\r\nbuoh(0.1\r\nbw·d(-1)(low\r\nbw).gp iv\r\nc-18)\r\nc-3/c-4 of →2)-α-l-rhap-(1→.\r\nc-c motif) ligand 2\r\nc-c motif) ligand 3\r\nc-ncad(838-856\r\nc-terminal sequence leu-trp-nh(2\r\nc.808 (g>t\r\nc(12)h(10)n(4)·2c(8)h(8)o(2\r\nc(12)h(14)n(2)o(4\r\nc(14)o(2\r\nc(18\r\nc(18\r\nc(19\r\nc(ave\r\nc(in\r\nc(max\r\nc(max\r\nc(p)/c(bc\r\nc(ss\r\nc).the lipid profile\r\nc++\r\nc++ programming language\r\nc57bl/ksj-db/db (db/db\r\nca²(+\r\nca2+)\r\nca2+)\r\ncacit vitamin d30(r\r\ncancer prev res (\r\ncand+hctz)\r\ncarbomer 934p (\r\ncarbopol(®\r\ncarboxymethyl sesbania gum-2.5%(w/v\r\ncardiac hazards;(2\r\ncardiotoxin- (\r\ncarpolobia alba (\r\ncases.(abstract truncated\r\ncases.(abstract truncated\r\ncassia obtusifolia l. (\r\ncastration.(abstract\r\ncastration.(abstract\r\ncav-1(-/-\r\ncb(1\r\ncb[6\r\ncbdiet (p<.0001\r\ncbl) deficiency\r\ncck-8) assay\r\ncd11b(+) gr1(+\r\ncd11c(+)cd206(+\r\ncd2+)\r\ncd34(+)/cd7(-)/cd4(-\r\ncd44(+)cd117(+\r\ncd44(pos)cd24(low/neg\r\ncd45-cd34+)\r\ncd8(+))\r\ncdkn1a(tmi/tyj)/j p21(-/-\r\ncell proliferation)-\r\ncell/mm(3\r\ncells.(abstract truncated\r\ncellular mode(s\r\ncervical-vaginal fluid(cvf\r\nchcl3-cc) fraction\r\nchemwell® 2910 (\r\nchi(2\r\nchinese)/ xiao bojian\r\nchinese)/xiao bojian\r\nchorionic gonadotropin loadings.(abstract truncated\r\nchorionic gonadotropin loadings.(abstract truncated\r\nchronic renal insufficiency cohort) study\r\nci(0.55\r\nci)=[-1.47\r\nci)=0.75\r\nci]=0.06%(-1 mmol/mol\r\ncidophage®)\r\ncilag (switzerland\r\ncilag (switzerland\r\ncirculating e(2\r\nck14+)\r\ncl(-\r\ncl(cr\r\ncl(int\r\ncl(nr\r\ncl(r\r\ncl(renal\r\ncl(sec\r\nclass 5([women])/6([men\r\nclerodendrum volubile)\r\nclinicaltrials.gov (nct01885013\r\nclinicaltrials.gov (nct02588859\r\nclomiphene citrate alone.(i-a\r\nclomiphene) trial\r\ncm[range\r\ncnox-2(+\r\ncntf(ax15\r\nco-ip) assays\r\nco(2\r\nco2·(-\r\ncoenzyme q10 (\r\ncoherent anti-stokes raman scattering) microscopy\r\ncohort 2)\r\ncombination)-may\r\ncon a)-\r\ncon)\r\nconcentration.(abstract truncated\r\nconclusion(s\r\ncondition(s\r\nconnexin 43 (\r\ncontinued health) registry\r\ncontrast-induced nephropathy(cin\r\ncontrol (c\r\ncontrol group(t=6.472\r\ncontrol metformin-treated (ct\r\ncontrols.(abstract truncated\r\ncontrols.(abstract truncated\r\ncontrols.(abstract truncated\r\nconventional immediate-release (ir\r\ncopper-bis(thiosemicarbazones\r\ncopper(ii\r\ncortisol) levels\r\ncortisol) levels\r\ncox) pathway\r\ncpm/10(6\r\ncrc(1.670\r\ncreatinine-based ckd-epicrea (\r\ncreatinine(crea\r\ncs-137) behavior\r\ncsf1-deficient csf1(op)/csf1(op\r\ncsf1(op\r\ncsf1(op)/csf1(op\r\ncsfm(op\r\ncsii.(abstract truncated\r\ncu (ii\r\ncu(c(19)h(17)n(5)o(5\r\ncu(cl)2(met)(en\r\ncu(ii)4(bpp)4(maa)8(h2o)2).2h2o\r\ncucl2(c19h16n4o\r\ncurve(0\r\ncurve(0-τ\r\ncyclic gmp/10(8\r\ncyclophosphamide-methotrexate-5-fluorouracil)\r\ncytochrome p450)\r\ncytosolic nadh/nad(+\r\nd-ser(bu)6-lh-rh(1\r\nd-ser(bu)6-lh-rh(1\r\nd(1\r\ndaudi (burkitt\r\nday-1)/placebo\r\ndays)-treated\r\ndb/db)\r\ndeath.(3\r\ndecreasing j(max\r\ndel(17p\r\ndelta phi(m\r\ndeltahba1c (hba1c\r\ndendritic poly(l-lysine\r\ndenmark) treat-to-target\r\ndepression(r=0.627\r\nder(11\r\nder(21\r\ndesogestrel/ethinyl oestradiol tablets(group b\r\ndetection bias.(a\r\ndhea\\dheas\r\ndiabetes symptom checklist-revised (dsc-r\r\ndiabetes symptoms checklist-revised (dsc-r\r\ndiabetic control) mice\r\ndiabetics.(abstract truncated\r\ndiabetics.(abstract truncated\r\ndiane-35(md group\r\ndiane(35\r\ndied.(abstract\r\ndiet-streptozotocin- (stz-\r\ndihydrotestosterone(dht\r\ndiji(sp\r\ndimethoate (organo-phosphorus\r\ndimethoate (organo-phosphorus\r\ndimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide\r\ndimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay\r\ndipeptidyl-peptidase-4 [dpp-4]-inhibitors\r\ndisease-free survival(dfs\r\ndmldlr(-/-\r\ndocosahexaenoic acid(dha\r\ndose 10(-7\r\ndose- (\r\ndose-dependent increase(p<0.05\r\ndose-normalized c(max\r\ndose(50 \r\ndownstream target p-p70s6k(thr389\r\ndpp-ivi)\r\ndpp4(+/+)\r\ndrug byetta(®\r\ndrug treatment.(3\r\ndrug-ta(cyd products\r\ndsm-iv-tr (\r\ndsm-iv-tr)\r\nduragesic®)\r\ndyes.(abstract\r\ndyes.(abstract\r\ne(-y\r\ne(1\r\ne(2\r\ne(f\r\ne(max\r\neach).the groups\r\neampk(flox/flox\r\nec(50\r\necstasy')\r\neffect(s\r\neffects)\r\negg)\r\nempagliflozin/linagliptin (emg/lig\r\nendothelial cells(ecs\r\nendpoint hba(1c\r\nendpoint(s\r\nenergy) diet\r\nepcam(+\r\ner-/pr-/her2+)\r\nerectile dysfunction(ed\r\nerectile function 15)\r\nerk(1/2\r\nestrogen receptor-positive (er(+)\r\nestrogen)\r\nestrogen)-high\r\nethinyl e(2\r\nethylene glycol)-b-poly\r\neucreas®)\r\neudragit(\r\neutirox®)\r\nevidence).four\r\nevidence).four trials\r\nevidence).human menopausal gonadotrophin\r\nevidence).one trial\r\nevidence).the\r\nevidence)the\r\nexd-(9\r\nexenatide/metformin/biphasic insulin aspart) therapy\r\nexendin(9-39\r\nexposure (\r\nexposure)\r\nf(1\r\nf(1,46\r\nf(2,54\r\nf(t\r\nfa/-)\r\nfabp4(ap2\r\nfao) cells\r\nfasting blood glucose(fbg\r\nfasting glucose/22.5)\r\nfeminization(gynecomastia etc\r\nfemoral artery(sfa\r\nferritin h) genes\r\nfixed-dose combination therapy(fdc\r\nfixed-dose combination/coad)\r\nflk-1(+)/sca-1(+\r\nfluorescent analog 2-[n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose\r\nformula 1/(log(10\r\nforxiga®)\r\nfour-unit poly(ethylene glycol\r\nfpqsflprg-nh(2\r\nfree t4(r=0.784\r\nft(4\r\nfull ms/dd-ms(2\r\nfull text (free\r\nfull-length hydra alpha1(iv\r\nfumes.(abstract\r\nfumes.(abstract\r\nfunction.(abstract\r\nfunction.(abstract\r\nfunctional assessment of cancer therapy-breast (fact-b\r\ng protein-coupled receptor 43/41 (\r\ng-allele (\r\ng. d. searle & co.)\r\ng. d. searle & co.)\r\ng.d.m. (o.r.\r\ng(0)/g(1\r\ng(1\r\ng(f\r\ng)-cyproterone acetate\r\ng/(kg\r\ng/kg)-combinations\r\ng/kg)-treated groups\r\ng401s (g\r\ng6pc (\r\ng6pc)\r\ngastric mucosal prostaglandin e(2\r\ngastrointestinal (gi\r\ngen(100\r\ngeneral erectile function(χ²=54.433\r\ngenetic kk-a(y\r\ngermany (disease analyzer\r\ngetgoal-s) study\r\nginkgo) partners\r\ngk(wt/del\r\nglibenclamide auc(3\r\nglibenclamide/glimepiride)\r\nglimepiride c(max\r\nglp-1(9-36\r\nglp1r(+/+\r\nglp1r(+/+)\r\nglucagon-like peptide-1(7\r\nglucophage (lipha\r\nglucophage xr)*\r\nglucophage(r\r\nglucophage®)\r\nglucose auc(0\r\nglucose-6-phosphatase (\r\nglucose-6-phosphatase (g6 pase\r\nglucose-6-phosphatase (g6pase\r\nglucose-6-phosphatase) metabolism\r\nglut3-specific antiserum.(abstract truncated\r\nglycated haemoglobin a(1c\r\nglycated haemoglobin a1(c\r\nglycated hemoglobin a(1c\r\nglycogen synthase kinase-3[formula\r\nglycoslyated hemoglobin a(1c\r\nglycosylated haemoglobin a(1c\r\nglycosylated hemoglobin a(1c\r\nglycosylated hemoglobin a1c(hba1c\r\ngn-rh) analogue\r\ngn-rh) analogue\r\ngnrh-like peptide(s\r\ngnrh-like peptide(s\r\ngnrh3) systems\r\ngroup 1(control\r\ngroup.(abstract\r\ngroups(n=10\r\ngrowth/(ingestion-egestion\r\ngsk- 3β) pathway\r\ngtp gamma s) assay\r\nh(2)o(2\r\nh)-treated cells\r\nhaemoglobin a(1c\r\nhaemoglobin a(1c)(hba(1c)\r\nhaemoglobina(1c\r\nhb a(1c\r\nhba(1\r\nhba(1c\r\nhba(₁c\r\nhba(1c) (\r\nhba(1c)).[primary endpoint\r\nhba(ic\r\nhba(lc\r\nhba[1(c\r\nhba1(c\r\nhba₁(c\r\nhba1c(10.2\r\nhbat1c(%\r\nhc)/liver x receptor α\r\nhco(3\r\nhcy)\r\nhdl(3\r\nhealthcare (\r\nhemoglobin (hb)a(1c\r\nhemoglobin a(1)c(hba(1)c\r\nhemoglobin a(1c\r\nhemoglobin a1(c\r\nhemoglobin a1c)\r\nhemoprotein(s\r\nher-2/neu +)\r\nher-2+)\r\nher2)-negative breast cancer\r\nher2+)\r\nher2+/er-/pr-) cell lines\r\nheteronuclear single quantum coherence)-filtered\r\nhgcl(2\r\nhif-2α)-can\r\nhigh let)-irradiated cell lines\r\nhigh-density lipoprotein (\r\nhigh-fat diet-streptozotocin- (stz-\r\nhigh-quality evidence).women\r\nhighly-active antiretroviral therapy)-associated lipodystrophy\r\nhinterteil (hint\r\nhis(69\r\nhispanic (his\r\nhl(2\r\nhmg-coa synthase 1(hmgcs1\r\nho8910-pm)             \r\nhoma-beta) index\r\nhoma-β(p\r\nhoma(beta-cell\r\nhoma(ogtt\r\nhoma<3.8)\r\nhong kong)\r\nhplc-ms(n\r\nhplc-ms/ms) technique\r\nhr.(abstract truncated\r\nhrb).second-generation sulphonylureas\r\nhtn(doc\r\nhtt)\r\nhuman papilloma virus-(hpv-\r\nhydra biology(1\r\nhydra piwi-like (hyli\r\nhydra tcf (hytcf\r\nhydra viridissima)\r\nhydra) blood cells\r\nhydrogen (h2\r\nhydrogen (h2\r\nhydroxyurea (hu\r\nhypericum (kira\r\nhypnotic drug(s\r\nhypoglycemic episode(s\r\nhypogonadism(testicular atrophy\r\nhypothalamic-pituitary-adrenal (\r\nhypothalamic-pituitary-adrenal (hpa\r\nhypoxia-inducible factor- (\r\nhypoxia-inducible factor- (hif-\r\nhyvab®)\r\ni(2\r\ni(amiloride\r\ni(control group\r\ni(f\r\ni(ouabain\r\nic(50\r\nic(50\r\nic(50\r\nid(2\r\nie(isr\r\nifca2+)\r\nigf-1r (tyr1165/1166\r\nigf-1r) signaling pathway\r\nigf-1r[tyr1165/1166\r\niglar(187 subjects\r\nii)\r\niief(1vs2\r\niief(1vs3\r\niief(2vs3\r\nileum.(abstract truncated\r\nimmunoreactive (ir\r\nindex group)-\r\nindex hba(1c\r\nindian hh (\r\nindication(s\r\ninducer)-induced\r\ninducible(i\r\ninhibitory factor(mif\r\ninhibitory substance(s\r\ninorganic zn(se\r\nins2(+/akita\r\ninsulin levels(ir\r\ninsulin resistance index ln(homa-ir\r\ninsulin treated (i\r\ninsulin x glucose)/22.5\r\ninsulin-resistance (ir\r\ninsulin.(abstract truncated\r\ninsulin(auc\r\ninsulin(p=0.014\r\ninsulin)-only\r\nintercellular signals.(abstract truncated\r\ninterleukin 10)\r\ninterleukin-6(il-6\r\ninterleukin‑6 (il‑6\r\nintermediate- (\r\ninternational continence society (ics)-\"bph\" (ics-male\r\ninternational units/litre (iu/l\r\ninterquartile range) disease\r\nintervention(s\r\nintra))/delta(inter\r\nintraduodenal (id\r\nintramuscular (\r\nionic/ag(+\r\nip)-streptozotocin\r\nipmk(-/-\r\nirs1-pser(307\r\nirs1-ser(312\r\nirs1(ser636/639\r\nirβ(tyr\r\nisi(ogtt\r\nisr(0-2h\r\njanumet ®)\r\njanumet(tm\r\njanumet®)\r\nk-ras(+/lsl-g12d);trp53(+/lslr172h);pdx-1-cre\r\nk(atp\r\nk(b\r\nk(d\r\nk(d\r\nk(e\r\nk(i\r\nk(m\r\nk)/serine-threonine kinase(akt)pathway\r\nk[atp\r\nk+ channels.(abstract truncated\r\nk121q (rs1044498\r\nk2(c3n3o3h\r\nk562 cells(p<0.05\r\nk562r (imatinib-resistance\r\nkcal/min/kg/10(3\r\nkg).we\r\nkg/cm(2\r\nkg/m(2\r\nkg⁻¹ day)⁻¹\r\nki-67+)\r\nkinase(pi3k\r\nkinase)/akt\r\nkk-a(gamma\r\nkmno(4\r\nkomboglyze®)\r\nkras(+/lslg12vgeo);elas-tta/teto-cre\r\nl-lactic-co-glycolic acid)-block-poly(ethylene\r\nl-t(4\r\nl. (family\r\nl.)\r\nl.) dunal\r\nl.) merr\r\nl.) urban\r\nl.mol(-1).s(-1\r\nl+g (10.57+/-1.97\r\nlady prelox®)\r\nlambda(max\r\nlancet 380(9840\r\nlantus®) once daily\r\nlate september) bulls\r\nlc-ms(n\r\nlc(50\r\nlc(50\r\nlc(50-90\r\nlc/ms/ms) method\r\nld(50\r\nldl(2\r\nldl(c\r\nleft ventricular (lv\r\nlent-soma) scales\r\nlepr q223r) genes\r\nlepr(db/db\r\nleptin receptor-deficient) mice\r\nlevels(53\r\nlevonorgestrel-releasing (mirena\r\nlgals3(+/+)\r\nlibido (desire\r\nlibido (t\r\nlibido.(abstract truncated\r\nlibido.(abstract truncated\r\nlibido\" (\r\nlight chain 3)-ii levels\r\nlight-cycler 480 (roche\r\nlimax pseudoflavus (\r\nlipitor®)\r\nlipoprotein lipase(lpl\r\nlipoprotein(a\r\nliquid co(2\r\nliviel(r\r\nlkb1(s\r\nln(ki-67\r\nlocal health unit of caserta (southern italy\r\nlocal.(abstract\r\nlocal.(abstract\r\nlocally advanced/advanced) disease\r\nlog(cac\r\nlog(tg/hdl-c\r\nlow dose(5\r\nlow s(i\r\nlow- (\r\nlow-density lipoprotein (\r\nlow-density lipoprotein (ldl\r\nlow-glycemic index) diet\r\nlow-quality evidence).• coasting\r\nlow)/cd34(+)/vegfr2(+\r\nlowering hemoglobin a(1c\r\nlp(a\r\nlp(a).(abstract truncated\r\nlp[a\r\nlsl-k-ras(g12d/+)/pten(floxp/floxp\r\nlsl-kras(g12d\r\nlss-derived auc(0,24\r\nlt-nes) cell lines\r\nlvdp/dt(min\r\nlw-amide(s\r\nm-echo signal)\r\nm(-\r\nm(2)[chronic kidney disease\r\nm(r\r\nm(w\r\nm(η\r\nm)-insulin\r\nm2[p \r\nma(m\r\nmanganese(iii\r\nmarketscan®)\r\nmastectomy(ssm\r\nmate1(+\r\nmcal de kg(-1\r\nmean auc(0-t\r\nmean haemoglobin a(1c\r\nmean hba(1c\r\nmean hemoglobin a(1c\r\nmean(±sd\r\nmean(sd\r\nmeasure sexual cognition/fantasy (desire\r\nmechanism(s\r\nmechanisms(s\r\nmenopause-specific quality of life) questionnaire\r\nmercury(ii\r\nmesenteric et(a\r\nmet (metformin\r\nmet (t1\r\nmet-p 33.8(5.2\r\nmet(-\r\nmet(+\r\nmetabolic syndrome (mefisto)(8\r\nmetformin (shiguibao\r\nmetformin 5 x 10(-4\r\nmetformin auc(0-∞\r\nmetformin c(max\r\nmetformin t(max\r\nmetformin-d(6\r\nmetformin-nickel(ii\r\nmetformin-treated (m\r\nmetformin,(500\r\nmetformin(1-(diaminomethylidene)-3,3-dimethyl-guanidine\r\nmetformin(50 microm\r\nmetformin(p \r\nmetformin) trial\r\nmetformin/tacrolimus (met/t\r\nmeth(2)(++)•2dca(-\r\nmethyl cellulose) sedentary\r\nmethylglyoxal-bis(guanylhydrazone\r\nmethylglyoxyl bis(guanylhydrazone\r\nmg)/ee\r\nmg)/levonorgestrel\r\nmg/(100 g•d\r\nmg/(kg body weight\r\nmg/(kg day\r\nmg/1000 mg)-glimepiride\r\nmg/kg(2\r\nmg/kg)-induced\r\nmg/kg)+nifedipine\r\nmg/kg)+rapa\r\nmg2+)\r\nmgso(4\r\nmicrog)-cyproterone acetate\r\nmitrocoma(halistaura\r\nml.min(-1\r\nml).comparing\r\nml/kg)-treated\r\nmlmin(-1\r\nmm(-2)s(-2\r\nmm(mri\r\nmm)-stimulated\r\nmmol l(-)(1\r\nmmol/mol)-10\r\nmoderate-quality).inconclusivelifestyle\r\nmodified ferriman-gallwey (mf-g\r\nmodified intent-to-treat) populations\r\nmolecular interaction(s\r\nmolecular mechanism(s\r\nmolecule(s\r\nmolecule(s\r\nmondia whitei hook (skeels\r\nmonths)--efficacy\r\nmpp(+\r\nmrna(1.18+/-0.06\r\nms(-\r\nms(+\r\nms(+)tds(-\r\nms(+)tds(+\r\nmsf-4 item) questionnaire\r\nmt-trna(trp\r\nmtb) elimination\r\nmtor(ser-2481\r\nmtor)-dependent ones\r\nmtor1) signaling\r\nmultidrug resistance(mdr\r\nmultivariate) regression modelling\r\nmyoinositol(600 \r\nn-(hydra zinocarbonyl)amino]-4-amino-3,6-disulfonato-1,8-naphthalimid e)\r\nn-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-n-(2,2,2-trifluoroethyl)benzenesulfonamide\r\nn-dimethylcarbamimidoyl)guanidine\r\nn-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium\r\nn-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]ethanaminium iodide\r\nn-trimethyl-2-[methyl(7-nitrobenzo[c][l,2,5]oxadiazol-4-yl)amino]ethanaminium iodide\r\nn(ω\r\nna(+))\r\nna(2)co(3\r\nna+-k+-atpase (\r\nnad(+\r\nnadh/nad(+\r\nnational institute of health (clinicaltrials.gov\r\nnational institutes of health (nih\r\nnatural anagen-inducing signal(s\r\nnct00451399(study 1\r\nne768(frua\r\nnetherlands (boxmeer\r\nneurological (n\r\nnew vanadium(iv\r\nnfκb(p65\r\nnh(2\r\nni(ii\r\nnijmegen (netherlands\r\nnine-day syncro-mate-b((r)\r\nno. chictr-iir-16007901)\r\nno/cgmp) pathway\r\nnocturnal penile erection(χ²=29.815\r\nnominal p=0.0084)\r\nnon insulin-dependent) diabetes\r\nnon-caucasian population.(abstract truncated\r\nnon-caucasian population.(abstract truncated\r\nnon-diabetic (control\r\nnon-high-density lipoprotein (\r\nnon-ovlon (ethinylestradiol\r\nnon-steady-state [3\r\nnon-use (\r\nnormo-glycemic condition(group 3\r\nnormoxia-conditioned (cn\r\nnovo nordisk inc) therapy\r\nnovolog(®\r\nnovorapid®)\r\nnuclear factor kappa-b(nf-kb\r\nnuclear factor kappa-b(nf-κb\r\nnuclear factor-kappa b(nfkb\r\no-p (χ(2) \r\no-tetradecanoylphorbol-13-acetate (tpa\r\no.d.)+glimepiride\r\no(.-)(2\r\no(2\r\no(2).(-\r\no1(+)/mbp(+\r\no2(∙-\r\noad(s\r\noads(metformin\r\nobtained.(abstract truncated\r\nocular) status\r\nodds ratio[or\r\nogtt-derived auc(ins/gluc\r\noha(s\r\noil (o\r\nold(er\r\nonoo(-\r\noption(s\r\nor[95%ci\r\nor[95%ci]=5.63[0.42-76\r\noral 14c-glucose)\r\noral antidiabetic agent(s\r\norganoiridium(iii\r\noros(r\r\novid) databases\r\noxaliplatin)-based chemotherapy\r\noxido-vanadium(iv\r\np-akt(ser473\r\np-irs-1(tyr895\r\np-methoxyformylbenzene-5-(1-phenyl-3-methyl-4-nitropyrazolyl\r\np(app\r\np(f\r\np(i(max\r\np(interaction\r\np(lifestyle*snp\r\np<0.001).the\r\np<0.001)and\r\np<0.02)and se-selectin\r\np<0.05),with\r\np=0.62).no lactic acidosis\r\np16(ink4a\r\np21(waf/cip\r\np21(waf1\r\np21(waf1/cip1\r\np27(kip1\r\np38) signaling\r\np53(-\r\np53(+/+)\r\np53+)\r\np70(s6k\r\np70s6k thr(389\r\npai1).there\r\npampk(ser173\r\npampkα(thr172\r\npancreatic cancer(pac\r\npapp-a-generated n-terminal (\r\nparathyroid hormone(pth\r\nparental-(snu-c5\r\npatient's hemoglobin a(1c\r\npausene(r\r\npbh(+\r\npcdna3.1(+\r\npce/(pce \r\npcos-vas1(facial hair\r\npcos(pre-metformin\r\npd-1(pdcd1\r\npd10[dose\r\npdx1(+\r\npeak e(2\r\npeak vo(2\r\npennsylvania)\r\nperiod.(abstract truncated\r\nperiod.(abstract truncated\r\nperitoneal dialysis(pd\r\npg)\r\npge(2\r\npgf(2alpha\r\npgf(2alpha\r\nphase) dysfunction\r\nphenformin.(abstract truncated\r\nphenyl)-2-propenoic acid\r\nphenyl)-2-propenoic acid\r\nphi(b\r\npi-3,4,5-(po(4))(3\r\npi3 kinase)/protein kinase b\r\npi3k)\r\npi3k) inhibitors\r\npi3k) pathway\r\npi3k) pathways\r\npim(s\r\npimephales promelas)\r\npio+pc)\r\npip(3\r\npk/pharmacodynamic (pd\r\npka) signaling\r\npkc-ζ(t410a\r\nplacebo-subtracted hba(1c\r\nplantago ovata f.)\r\nplasma glucagon-like peptide-1(glp-1\r\nplutonium(iv\r\npmol/(min\r\npo(2\r\npocl(3\r\npoint.(abstract truncated\r\npoint.(abstract truncated\r\npoly (i\r\npoly(3-hexylthiophene\r\npoly(acrylic acid\r\npoly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol\r\npoly(lactic acid\r\npoly(lactic-co-glycolic acid\r\npoly(magnesium acrylate\r\npoly(methyl methacrylate\r\npoly(styrene-alt-maleic anhydride\r\npoly(thioetheramido acid)-poly(ethylene glycol\r\npoly(vinyl pyrrolidone\r\npossible.(abstract\r\npossible.(abstract\r\npost-antide.(abstract truncated\r\npost-antide.(abstract truncated\r\npostprandial glucose(ppg\r\nppar(peroxisome proliferator\r\npparγ +/-)\r\npparγ(2\r\nprandin®)\r\nprasterone®)\r\nprcre/+ ptenflox/+)\r\npremixed insulin lispro 25)\r\nprocess.(abstract truncated\r\nprocess.(abstract truncated\r\nprolactin(hprl\r\nprolonged t(max\r\nprostaglandin e(1\r\nprostaglandin e(2\r\nprostaglandin el1(pge1\r\nprostaglandin f(2alpha\r\nprostaglandin f(2α\r\nprostaglandin f2 alpha tham salt(pgf\r\nprostaglandin f2 alpha tham salt(pgf\r\nprotein kinase cα) activity\r\nprotein(s\r\nprous science integrity(r\r\npseudo-erotic) strivings\r\npsychopathy checklist-revised (\r\npten(+/-\r\npubmed(r\r\nq-q graphics).to\r\nq(max\r\nq)\r\nq10 (coq10\r\nqjm(h\r\nqtern®)\r\nquality.(abstract truncated\r\nquality.(abstract truncated\r\nquality(ahrq\r\nr(10h\r\nr(85\r\nr(d\r\nr(g\r\nr(hf\r\nr460x (nt7605c\r\nr61c (rs12208357\r\nrajasthan (india\r\nrandomized clinical trials(rcts\r\nrapamycin)-mediated\r\nrcp(11;21)(q28;q12\r\nreactive oxygen species(ros\r\nreactive oxygen species)/redox balance\r\nreason(s\r\nreceptors(er\r\nreciprocal ldl(1\r\nreduced hemoglobin a(1c\r\nregression trees) procedure\r\nrenal transporter(s\r\nreply.(abstract truncated\r\nrespectively)--inhibited\r\nrespectively).(abstract truncated\r\nrespectively).in conclusion\r\nrespiratory o(2\r\nretinoic acid 10(-6\r\nretrospective) trials\r\nretrospectively registered) isrctn75758249\r\nrho(0\r\nrio-t2d)\r\nriomet®)\r\nrole(s\r\nrole(s\r\nros)-resistant\r\nrosa26(r899x\r\nrr=1.01[95\r\nrti-4587-073(l\r\ns-3-(4-nitrophenoxy\r\ns.d. 2.9)%\r\ns(6\r\ns(g\r\ns(i\r\ns)-nicotine\r\ns)/(k(m\r\nsaigon-dongnai river) vietnam\r\nsaliva orthana(®\r\nsanyinjiao\"(sp 6\r\nsatisfactory sexual event\" (\r\nsavor-timi 53 (\r\nsaxenda®)\r\nsc(otf)(3\r\nschizophrenia outpatient health outcome) study\r\nscience(tm\r\nscr (crea\r\nsecond-line glucose-lowering medication(s\r\nsecondary)\r\nsecondary)\r\nsecondary) diabetes\r\nser(235/236\r\nser(307\r\nser(473\r\nser(789\r\nser(79\r\nserotonin(2c-\r\nsert(-/-\r\nsert(+/-\r\nserum alpha-1-fetoprotein (\r\nserum e(2\r\nserum high-density lipoprotein (\r\nserum high-molecular-weight (hmw\r\nserum insulin (p=.044\r\nserum levels of testosterone(p<0.01\r\nserum microrna-29 (mir-29\r\nserum vitamin b(12\r\nserum vitamin b(12\r\nsex-matched rentgf-β1 (tg\r\nsexual dysfunction(s\r\nsexual dysfunction(s\r\nsexual inhibition\\sexual\r\nsexual life(χ²=21.211\r\nsexual life(χ²=70.445\r\nsexual) desire\r\nsft(max\r\nsh2b1 (rs7498665\r\nsi/al (p=0.042\r\nsicile (italy\r\nsignal(s\r\nsingle- (\r\nsirt1)-forkhead box protein o1\r\nsirtuin 1(sirt1\r\nsite.[3\r\nslc47a)\r\nslc5a2) inhibitors\r\nslc5a5) protein\r\nsm22-tsc1(-/-\r\nsmall high-density lipoprotein (\r\nsmd-1.05[-2.13,0.03\r\nso4(2-\r\nsodium n-[8-(2-hydroxybenzoyl)amino]caprylate\r\nsodium-[1\r\nsodium-glucose co-transporter-2 (\r\nsoftware qikprop(®\r\nsphygmocor (version 7.1\r\nsrc (\r\nstage iii) disease\r\nstage m1) disease\r\nstar(*)d study\r\nstata 14 (\r\nstop-niddm (study\r\nstreptozotocin- (stz-\r\nsubjective (\r\nsulfamethoxazole/trimethoprim (smz/tmp\r\nsweet tooth) domains\r\nswt(k/r\r\nsymptoms checklist-90-revised (scl-90-r\r\nsystem(pmrs\r\nt x a)\r\nt-allele (tt+tg\r\nt-test(s\r\nt(1/2\r\nt(20\r\nt(3\r\nt(3\r\nt(90\r\nt(lmet\r\nt(max\r\nt(y;21)(p11;q11\r\nt)\r\nt2(mm\r\ntbc1d4 thr(642)/ser(711\r\ntc(r\r\ntdt-mediated dutp nick-end labeling) assay\r\ntensin homolog) protein\r\nteratogenesis.(abstract truncated\r\ntesavel(r\r\ntestosterone (t\r\ntestosterone (t\r\ntestosterone(t\r\ntg(triglyceride\r\ntg(wt1b\r\ntg),high density lipoprotein\r\ntgf-beta(1\r\ntgf-β(1\r\nthiazolidinedione derivatives(tzds\r\nthiazolidinediones(tzd\r\nthiazoyl)-2,5-diphenyl-2h-tetrazolium bromide\r\nthin layer radiochromatography(tlrc\r\nthr(172\r\ntidal volume ≈7 ml/kg)\r\ntime- (\r\ntotal (t\r\ntotal.(abstract truncated\r\ntpp(+\r\ntr4(-/-\r\ntraining dexamethasone-treated (\r\ntrans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]cyclohexyloxy}benzoic acid\r\ntranscription factor(tf\r\ntransforming growth factor- (tgf-\r\ntransforming growth factor-β) signaling\r\ntransplantation patients(tx\r\ntrieste (italy\r\ntrigonella foenum-graecum l.) seed mucilage\r\ntris(2,2'-bipyridyl)ruthenium(ii\r\ntrna(leu\r\ntuberous sclerosis 1)/tuberin\r\ntumour necrosis factor-alpha)\r\ntype 2) diabetes mellitus\r\ntype ii)\r\ntyr(354\r\nu)/k(i\r\nuflc-ms/ms (\r\nuge(0\r\nultrasound) documenting\r\nunited states)-a fixed combination\r\nunited states[1\r\nuvrier canal (switzerland\r\nv(c(15)h(10)i(2)n(2)o(2))(ch(3)o)o(ch(3)oh\r\nv(d\r\nv(u\r\nv/f(apparent volume of distribution\r\nval(8))glp-1(glupal\r\nval8-glp-1(7\r\nvarthemia iphionoides boiss (compositae\r\nvascular k(atp\r\nvasculogenesis(a process\r\nve/vco(2\r\nvector-reaction-diffusion-drift (\r\nviagra(r\r\nvipdomet®)\r\nviral dsrna analogue poly(i\r\nvit b(12\r\nvitamin b(12\r\nvitamin d(3\r\nvo(2\r\nvo(2max\r\nw. volubilis(50\r\nw(d\r\nw(peak\r\nw\\o\r\nwaist)\r\nwaist)\r\nweekly intramuscular (im\r\nweekly intramuscular (im\r\nweibull) models\r\nweight) diet\r\nweighted mean glucose auc(0\r\nwestern blot)\r\nwith[1\r\nwomen.(abstract truncated\r\nwomen.(abstract truncated\r\nworld health organization) methodology\r\nx(1\r\nx(6β-ohf\r\nxp-v) gene\r\nzinc-α2-glycoprotein (\r\nzncl(2\r\nzucker lean (zl\r\nα (\r\nα and β)\r\nα(1\r\nα(4)β(2\r\nα1/2(-/-\r\nβ-[1-(14)c]hydroxybutyric acid\r\nδauc(gluc60\r\nδg(∗\r\nδi(30)/δg(30\r\nφ(s\r\n```","closed_by":null,"reactions":{"url":"https://api.github.com/repos/allenai/scispacy/issues/236/reactions","total_count":0,"+1":0,"-1":0,"laugh":0,"hooray":0,"confused":0,"heart":0,"rocket":0,"eyes":0},"timeline_url":"https://api.github.com/repos/allenai/scispacy/issues/236/timeline","performed_via_github_app":null,"state_reason":null}